On this page
Back to topHeartflow HTFL
Heartflow listed on Nasdaq on 8 Aug 2025 and is not in the S&P 500. It is worth $3.9 billion. Its board has 7 directors, 6 of them independent. 3 other officers are on file. At 30 Jun 2026, Bain Capital Life Sciences Investors was its largest institutional holder, with 9.8% of the company.
- CEO
- John C.M. Farquhar
- Chair
- William C. Weldon
- Listed
- 8 Aug 2025 on Nasdaq
- Headquarters
- San Francisco, CA
- Market cap
- $3.9B
- 19 Nov 2026 close
- Price to sales
- 22.3
- Market cap over revenue
Financials
Financial history
Twelve months to 30 Sep 2026, from Heartflow's quarterly filings.
Quarters since Jun 2024
- Revenue
- $239M
- Up 47% on the year before
- Net income
- $-79M
- -33.1% of revenue
- Free cash flow
- $-56M
- Operating cash flow less capital spending
- P/E
- -
- No profit over the last four quarters
Quarterly results
Each quarter's revenue, net income and free cash flow.
Jun 2024 to Sep 2026
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $73M | $-12M |
| Jun 2026 | $64M | $-16M |
| Mar 2026 | $53M | $-27M |
| Dec 2025 | $49M | $-24M |
| Sep 2025 | $46M | $-51M |
| Jun 2025 | $43M | $-9M |
| Mar 2025 | $37M | $-32M |
| Dec 2024 | $35M | $-33M |
| Sep 2024 | $33M | $-19M |
| Jun 2024 | $31M | $-23M |
Revenue breakdown
Heartflow's $73M of revenue, as its quarterly report splits it. Parts that are not a business, such as sales between segments, can be negative.
Quarter to Sep 2026
| Split by | Part | Revenue |
|---|---|---|
| Region | United States | $69M |
| Region | Rest of World | $4M |
Heartflow's market cap since August 2025
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $4.3B |
| 26 Dec 2025 | $2.5B |
Download Heartflow's data as JSON, with the weekly market caps in billions of dollars from 15 Aug 2025.
Board and leadership
Board and officers
1 person here also holds roles at other S&P 500 companies.
Board from the proxy filed 29 Apr 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (7) | |||||
| William C. WeldonChairIndependent · since 2014 · Nominating & Corporate Governance (chair)Former Chairman of the Board and Chief Executive Officer, Johnson & JohnsonOther boards: Fairfax Financial Holdings | |||||
| John C.M. FarquharChief Executive OfficerNot independent · since 2022 | |||||
| Timothy C. BarabeDirectorIndependent · since 2022 · Audit (chair)Retired Chief Financial Officer and Executive Vice President, Affymetrix, Inc.Other boards: Cartesian Therapeutics | |||||
| Julie A. CullivanDirectorIndependent · since 2020 · AuditFormer Chief Technology and People Officer, Forescout Technologies, Inc.Other boards: Axon Enterprises | |||||
| Jeffrey C. LightcapDirectorIndependent · since 2011 · Compensation, Nominating & Corporate GovernanceSenior Managing Director, HealthCor Partners Management, L.P. and Senior Managing Director, Healthcare Venture Partners, LLCOther boards: CareView Communications | |||||
| Wayne Joseph RileyDirectorIndependent · since 2021 · Audit, Compensation (chair)President, State University of New York Downstate Health Sciences UniversityAlso at HCA HealthcareOther boards: COMPASS Pathways | |||||
| Casey M. TanseyDirectorIndependent · since 2010 · Compensation, Nominating & Corporate GovernanceGeneral Partner, U.S. Venture PartnersOther boards: Inspire Medical Systems and Shoulder Innovations | |||||
| Officers (3) | |||||
| Vikram VergheseChief Financial OfficerLast filed 18 Sep 2026 | |||||
| Marie L. JonesChief Accounting OfficerLast filed 10 Aug 2026 | |||||
| Campbell RogersChief Medical OfficerLast filed 21 Sep 2026 | |||||
Owners and trading
Largest institutional holders
Each fund group's share of Heartflow. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $32.9 million of stock in 37 sales and bought $1.1 million in 1 purchase in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 17 Nov 2026Sale | Campbell RogersChief Medical Officer | $1.7M |
| 10 Nov 2026Sale | John C.M. FarquharChief Executive Officer | $2.2M |
| 9 Nov 2026Sale | Vikram VergheseChief Financial Officer | $191K |
| 22 Oct 2026Sale | Campbell RogersChief Medical Officer | $2.0M |
| 12 Oct 2026Sale | John C.M. FarquharChief Executive Officer | $1.9M |
| 18 Sep 2026Sale | Campbell RogersChief Medical Officer | $1.6M |
| 18 Sep 2026Sale | Vikram VergheseChief Financial Officer | $851K |
| 17 Sep 2026Sale | Vikram VergheseChief Financial Officer | $380K |
| 15 Sep 2026Sale | Vikram VergheseChief Financial Officer | $33K |
| 14 Sep 2026Sale | Vikram VergheseChief Financial Officer | $231K |
Showing 10 of 38 trades
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
14 large insider sales in the last two years.
Insider sales of $1 million or more, and the largest tenth of Heartflow's insider sales.
Events, newest first
- 17 Nov 2026 Campbell Rogers sold $1.7MChief Medical Officer
- 10 Nov 2026 John C.M. Farquhar sold $2.2MChief Executive Officer
- 22 Oct 2026 Campbell Rogers sold $2.0MChief Medical Officer
- 12 Oct 2026 John C.M. Farquhar sold $1.9MChief Executive Officer
- 18 Sep 2026 Campbell Rogers sold $1.6MChief Medical Officer
- 11 Sep 2026 Vikram Verghese sold $1.5MChief Financial Officer
- 10 Sep 2026 John C.M. Farquhar sold $1.6MChief Executive Officer
- 3 Sep 2026 Vikram Verghese sold $1.4MChief Financial Officer
Showing 8 of 14 events
| Date | Event | Filing |
|---|---|---|
| 17 Nov 2026 | Campbell Rogers sold $1.7MChief Medical Officer | Form 4 |
| 10 Nov 2026 | John C.M. Farquhar sold $2.2MChief Executive Officer | Form 4 |
| 22 Oct 2026 | Campbell Rogers sold $2.0MChief Medical Officer | Form 4 |
| 12 Oct 2026 | John C.M. Farquhar sold $1.9MChief Executive Officer | Form 4 |
| 18 Sep 2026 | Campbell Rogers sold $1.6MChief Medical Officer | Form 4 |
| 11 Sep 2026 | Vikram Verghese sold $1.5MChief Financial Officer | Form 4 |
| 10 Sep 2026 | John C.M. Farquhar sold $1.6MChief Executive Officer | Form 4 |
| 3 Sep 2026 | Vikram Verghese sold $1.4MChief Financial Officer | Form 4 |
| 21 Aug 2026 | John C.M. Farquhar sold $1.4MChief Executive Officer | Form 4 |
| 18 Aug 2026 | John C.M. Farquhar sold $1.5MChief Executive Officer | Form 4 |
| 24 Jun 2026 | John C.M. Farquhar sold $1.4MChief Executive Officer | Form 4 |
| 1 Apr 2026 | Campbell Rogers sold $2.0MChief Medical Officer | Form 4 |
| 19 Mar 2026 | Campbell Rogers sold $2.1MChief Medical Officer | Form 4 |
| 12 Feb 2026 | Campbell Rogers sold $1.6MChief Medical Officer | Form 4 |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.